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ABSTRACT
FANCM, the most highly conserved component
of the Fanconi Anaemia (FA) pathway can resolve
recombination intermediates and remodel synthetic
replication forks. However, it is not known if these
activities are relevant to how this conserved protein
activates the FA pathway and promotes DNA cross-
link repair. Here we use chicken DT40 cells to sys-
tematically dissect the function of the helicase and
nuclease domains of FANCM. Our studies reveal
that these domains contribute distinct roles in the
tolerance of crosslinker, UV light and camptothecin-
induced DNA damage. Although the complete heli-
case domain is critical for crosslink repair, a pre-
dicted inactivating mutation of the Walker B box
domain has no impact on FA pathway associated
functions. However, this mutation does result in ele-
vated sister chromatid exchanges (SCE). Further-
more, our genetic dissection indicates that FANCM
functions with the Blm helicase to suppress sponta-
neous SCE events. Overall our results lead us to
reappraise the role of helicase domain associated
activities of FANCM with respect to the activation
of the FA pathway, crosslink repair and in the
resolution of recombination intermediates.
INTRODUCTION
A fundamental defect in DNA repair causes Fanconi
Anaemia (FA), a genetic illness that leads to abnormal
development, bone marrow failure and cancer. As many
as 13 genes are known to be mutated in FA, most of
these physically and genetically interact to form the FA
genome stability pathway (1,2). A key question concerns
how such a pathway stimulates DNA repair. The identi-
ﬁcation of FANCM, a highly conserved gene in the FA
pathway, may shed light on this crucial question.
Vertebrate FANCM contains highly conserved amino
(N) terminal helicase and carboxy (C) terminal nuclease
like domains, which suggest that it participates directly in
DNA repair (3,4). This domain arrangement is identical
to that of the archaeabacterial FANCM orthologue Hef,
in which the activities of both domains are coordinated
to unwind and cleave a replication fork (5). Recently,
FANCM N-terminal helicase and C-terminal nuclease
domains have been shown to interact with HCLK2 to
promote the activation of DNA damage checkpoints (6).
The C-terminal nuclease domain of FANCM interacts
with a 24kDa protein (FAAP24) and this protein complex
binds to synthetic replication fork-like DNA structures,
preferentially to ssDNA, splayed-arm, and 30-ﬂap DNA
substrates (7). FAAP24 knock down abolishes DNA
damage inducible FANCD2 monoubiquitination and
leads to sensitivity to DNA crosslinking agents (7).
Biochemical studies of vertebrate and yeast FANCM
orthologues, FML (S. pombe) and MPH1 (S. cerevisiae),
have revealed that these proteins can bind Holliday junc-
tions and replication fork-structured DNA. Yeast and
human FANCM orthologues also promote fork regres-
sion, Holliday junction migration and can also unwind
RPA-stabilized D-loops (8–11). Furthermore, genetic
studies performed in yeast show that the FANCM ortho-
logues promote replication restart and suppress crossovers
following sister chromatid recombination after DNA
damage (9,12). It is important to emphasize here that
only translocase but not helicase activity has been
reported for the full length puriﬁed FANCM. In addition
close sequence analysis of the nuclease like domain does
suggest that key catalytic residues seem to be missing lead-
ing to the conclusion that this region does not confer
nuclease activity. Nevertheless taken together, these ﬁnd-
ings have led to the proposal that FANCM may move
along double-stranded DNA, sensing, remodelling and
restarting stalled replication forks.
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ing the biochemical functions of FANCM in diﬀerent
organisms, evidence about how these activities promote
DNA repair following DNA damage in vivo is limited.
The yeast orthologues, FML and MPH1, contain only
the N terminal helicase-like domain and lack both the
middle and C-terminal sections found in vertebrate
FANCM. Additionally, no other FA genes have been
identiﬁed in yeast to date. Therefore, it has not been pos-
sible to extrapolate the function of FANCM in the
FA DNA repair pathway from the reported in vivo activ-
ities of yeast FANCM orthologues.
To circumvent the diﬃculties encountered in expressing
transfected FANCM in either human or chicken FANCM
deﬁcient cell lines, Wang and colleagues have used a tran-
sient siRNA approach to knock down endogenous
FANCM expression in a human cell line. This cell line
was simultaneously complemented with siRNA resistant
FANCM cDNA. Using this approach they showed that
HeLa cells harbouring a point mutation in the ATPase
Walker A sequence of FANCM were defective in crosslink
repair despite being competent in FANCD2 monoubiqui-
tination (13). This result therefore strongly suggests that
the translocase activity of FANCM imparts crosslink
repair function.
This work addresses the functions of the distinct
domains of chicken FANCM in DNA repair. We system-
atically dissect how diﬀerent domains of this large protein
function to activate the FA pathway and promote DNA
crosslink repair. Furthermore, our genetic analyses
uncover two new functions of FANCM that do not over-
lap with its role in the FA pathway: UV and camptothecin
induced DNA damage tolerance. Finally we discover a
role for FANCM in the suppression of crossover recom-
bination with the Bloom’s (BLM) helicase.
METHODS
Gene disruption of the chicken FANCM locus
The chicken FANCM locus was identiﬁed by BLAST
search using the human protein sequence against the
ENSEMBL draft chicken genome sequence. An
ENSEMBL predicted transcript encompassed most of
the FANCM gene, although the 50 end, containing some
of the helicase motifs, was missing. The complete 50 end of
the gene was ampliﬁed by PCR and all exons encoding the
Mph1 like domain were identiﬁed. Sequence from the pre-
dicted and PCR ampliﬁed genomic DNA was used to
design the two gene disruption cassettes (A and B). PCR
oligos used to amplify 50 and 30 arms of construct A were
TCGTGACACTTAATCCCTCGGTGCTCTGAGC/GA
AGGGCGACAAAACCAACTTCCC and AGGCTGTG
CAGCAGGTTGTTTCCAA/TGCAACACACAGCGT
GACACCCAGT, respectively. Those for the knockin
construct B were 50 arm: AGCGGCGCTGGTCTATAT
CTTTAGGG/GCAGACAGCGCTGAGGGGAATACA
and 30arm ACCAAAAGCTGATGGACATCCAAAT
CC/AGTTGCCATAGGAAATGATGTTGGTGTCAG.
PCR products were cloned into pCR2.1-TOPO
(Invitrogen) and then the D203A point mutation was
introduced using Stratagene QuickChange XL site direc-
ted mutagenesis kit and the following primers: GTTAAA
TGCTTGGTTGTTGCCGCGGCCCACAAAGCTCTG
GG/CCCAGAGCTTTGTGGGCTTCGGCAACAACC
AAGCATTTAAC. Transfections, selection and Southern
analyses of targeted DT40 clones were carried out as
described previously (4,14). The lox drug resistance cas-
sette was removed by transiently transfecting cell lines
with the Cre recombinase NLS-expression plasmid.
Cells were cloned by limiting dilution and then tested indi-
vidually for loss of drug resistance. To conﬁrm the appro-
priate disruptions of the GgFANCM locus the following
PCR oligos were used; F1, TTTGGGACGGGAATAGA
GC; R1, GCCACCTCCTTTCCTCTAT. Generation of
BLM FANCM-D203A knockin cell line was carried
out by targeting sequentially FANCM-D203A Knockin
and FANCM-hel constructs into the BLM strain [kind
gift from Professor Enomoto (19)]. 50 and 30 arms of the
FANCC in situ TAP-tagged construct were generated as
described before (4).
Flag-tag constructs were ampliﬁed using chicken
FANCM cDNA using forward primers CCGAGATCT
CACCATGGATTACAAGGATGACGACGATAAGG
ACTATAAGGACGATGATGACAAGAGCGGCGGC
CGGCAGCGCACCCTGCCC for the +HEL construct
and CCGGGATCCCACCATGGATTACAAGGATGA
CGACGATAAGGACTATAAGGACGATGATGACA
AG GGGGATTGCAGCTATGAACTGGAGCTT for
either +LMS or +NUC constructs and reverse primers
CCGAGATCTTCCTTCAGCAGGAAACACACGTGA
G for the +HEL construct, CCGGGATCCTCCTTCAG
CAGGAAACACACGTGAG for the +LMS construct
and CCGGGATCCAGCGGCCGCTCAGCTCCTGC
TG for the +NUC construct. These PCR products were
cloned into pCR-TOPO and veriﬁed by sequencing. These
fragments were cloned from pCR-TOPO into the expres-
sion plasmid pEXPRESS and checked for orientation.
Expression cassettes were cloned into drug resistance cas-
sette-containing pLOX plasmids. Proteins expression was
conﬁrmed by western blot.
Mutagen sensitivity assays
For cisplatin survival assays cell lines were plated into
96-well plates at a density of 3000cells per plate. A
range of doses of cisplatin was added to wells, and the
plates were returned to the incubator for ﬁve complete
cell-doubling times. After this the cells were pulsed with
MTS (Promega) and incubated for another 1h. Cell via-
bility was measured by luminometry according to manu-
facturer’s instructions (Promega), and each dose point was
assayed in triplicate. The colony survival values plotted
are relative to an untreated control.
For UV sensitivity, cells were irradiated with the indi-
cated doses, diluted in medium and grown for 2 weeks in
methylcellulose containing plates. For camptothecin sen-
sitivity, cells were grown for 2 weeks in CPT-containing
methylcellulose plates. Plots represent the average of three
independent experiments. Error bars represent standard
deviation.
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Treated or untreated cells (10
9) were lysed in lysis buﬀer
(50mM Tris–HCl, pH 8.0, 0.5mM EDTA, 0.1% Triton
X-100, 200mM NaCl and protease inhibitor cocktail
(Roche Molecular Biochemicals)) with a Dounce homo-
genizer. Lysates were cleared by centrifugation using a
Beckman rotor Ti45, at 48C and 35000r.p.m. for 60min.
Extracts (9mg total protein) were incubated for 2h at 48C
with 50ml IgG-Sepharose beads (Amersham). Precipitated
material was extensively washed with lysis buﬀer contain-
ing 500mM NaCl. Precipitated material was resolved by
4–12% Bis/Tris–SDS–PAGE (Invitrogen) and detected by
immunoblot with antibodies to Flag, GgFANCG, or TAP.
WesternblotanalysesforFANCD2weredoneasdescribed
previously (14). Detection of chicken FANCM was carried
out using antisera directed to the large middle section of
the chicken FANCM gene. The details of this reagent are
published in Mosedale et al. (4).
Cellular subfractionation
Two hundred million DT40 cells were treated with 1mM
cisplatin for 16h, harvested, washed once with PBS and
lysed in hypotonic buﬀer (10mM Tris–HCl pH 7.4,
10mM KCl, 1.5mM MgCl2, 10mM 2-mercaptoethanol)
by pushing cells through a 19G needle. Nuclei were col-
lected by centrifugation (2700g, 10s) washed twice with
hypotonic buﬀer and nuclear proteins were extracted with
a high-salt buﬀer (15mM Tris–HCl, pH 7.4, 1mM EDTA,
500mM NaCl, 1mM MgCl2, 10% glycerol, 10mM 2-mer-
captoethanol and protease inhibitor cocktail). To enrich
for chromatin-associated proteins, salt-extracted pellets
were treated with 1500units micrococcal nuclease (Amer-
sham) for 20min at room temperature in nuclease reaction
buﬀer (20mM Tris–HCl, pH 7.4, 100mM KCl, 2mM
MgCl2, 1mM CaCl2, 0.3M sucrose, 0.1% Triton X-100
and protease inhibitor cocktail). Comparable amounts
(relative to each fraction) were resolved on 4–16% Tris–
glycine gels (Invitrogen) by SDS–PAGE and analysed by
immunoblotting using anti-FLAG (sigma), anti PAP or
anti-histone H3 (Abcam) antibodies.
Gel-filtration analyses
High salt nuclear extracts were prepared with a few
modiﬁcations as described previously (4). Brieﬂy, proteins
were extracted from nuclei (isolated from 4   10
9 DT40
cells as indicated) with nuclear extraction buﬀer [15mM
Tris–HCl, pH 8.0, 0.2mM EDTA, 420mM NaCl, 1.5mM
MgCl2, 25% glycerol, 0.5mM DTT and protease inhibitor
cocktail (Roche Molecular Biochemicals)]. Cleared
nuclear extracts (3.5mg) were directly applied to a
Superose 6 HR16/50 column (Amersham) equilibriated
with column buﬀer (15mM Tris–HCl pH, 8.0, 0.2mM
EDTA, 420mM NaCl, 1.5mM MgCl2, 10% glycerol,
0.5mM DTT). Fractions (4ml) were collected and ali-
quots were resolved by 4–12% Bis/Tris–SDS–PAGE
(Invitrogen). FANCC-TAP was detected by immunoblot
analyses with an antibody to TAP (Sigma). FANCM and
FANCG were detected by immunoblot analyses with anti-
bodies raised against GgFANCM and GgFANCG,
respectively. The Superose 6 column was calibrated with
a high molecular weight calibration kit (Amersham).
SCE analysis in DT40 cells
We carried out SCE assays as previously described (14)
using 10mM BrdU for two cell cycles and adding 0.1mg
(per ml) of colcemid 2.5h before harvesting cells.
The slides were coded (therefore blinded to the observer)
and approximately 50 metaphases for each cell line were
scored.
RESULTS
Hypomorphic alleles of FANCM in DT40 show different
phenotypes
As a ﬁrst step to distinguish between the functions of the
distinct domains of FANCM, we disrupted the exons
encoding either the helicase (FANCM-hel) (Figure 1A)
or the nuclease domain (FANCM-nuc) (Mosedale
2004). DT40 strains carrying homozygous deletion of
either of these domains were then compared to the full-
length deleted FANCM (FANCM) strain in terms of
FANCD2 monoubiquitination and sensitivity to DNA
crosslinking agents (Figure 1B and C). When these cell
lines were exposed to high doses of cisplatin, we noted
that FANCD2 ubiquitination in the FANCM null cell
line was defective compared to wild-type, but importantly
was clearly detectable. However, deletion of FANCL
a member of FA core complex, completely abolished
FANCD2 monoubiquitination. In the FANCM-hel
cell line, FANCD2 monoubiquitination levels were also
diminished, but were unperturbed in the FANCM-nuc
cell line. We also measured the sensitivity to cisplatin of
the FANCM deﬁcient cell lines. The FANCM null cell line
was more sensitive to cisplatin than FANCM-hel, whilst
FANCM-nuc is not sensitive to this agent (Figure 1C).
This sensitivity partially correlates with the ability of these
cell lines to monoubiquitinate FANCD2. A feature of
all chicken DT40 FA pathway knockouts is the presence
of raised spontaneous sister chromatid exchange events
(SCEs) (14–17). FANCM deﬁcient DT40 cells display
increased numbers of spontaneous sister chromatid
exchanges (SCEs) (4). We therefore compared the levels
of SCEs in each FANCM mutant strain. The FANCM
(mean=9.0 SCEs per metaphase) and the FANCM-hel
(mean=9.2 SCEs per metaphase) strains show elevated
SCEs, whilst FANCM-nuc (mean=1.3 SCEs per meta-
phase) shows wild-type SCEs levels (Figure 1D). Double
mutants of genes involved in the FA repair pathway such
as FANCC/FANCG, FANCC/FANCA and FANCC/
FANCJ do not lead to an increase in SCEs compared
to respective single mutants, indicating that SCEs arise
by virtue of a common process (14,16). As FANCM is a
component of the FA core complex, we compared SCEs
levels in the double mutant cell line FANCM FANCC
and the respective single mutant strains. Strikingly, the
double FANCM FANCC strain (mean=14.9 SCEs
per metaphase) has more spontaneous SCEs than either
single knockout strain, indicative of an additive impact on
this phenotype. Cumulatively, these results suggest that
4362 Nucleic Acids Research, 2009, Vol. 37,No. 13the helicase but not the nuclease domain of FANCM is
required for crosslink repair and SCE suppression.
Complementation of the FANCM knockout with FANCM
domain-specific cDNA
Immunoblot analyses failed to detect residual FANCM
protein in any of these strains indicating that the respec-
tive disruptions did result in reduced protein expression.
However, since the phenotypes of FANCM-hel and
FANCM-nuc cells clearly diﬀered we believe that this
most likely reﬂects the creation of hypomorphic alleles of
FANCM (data not shown). To conﬁrm this, we generated
FANCM Flag-tagged domain speciﬁc over-expression
constructs (Figure 2A). These constructs consist of the
helicase domain with the large middle section (LMS)
of FANCM (+HEL construct), the LMS alone (+LMS
construct), or the LMS with the nuclease domain (+NUC
construct). LMS was included in all constructs since this
region contains the putative bipartite nuclear localization
signal. To monitor the FA core complex dynamics, we
expressed these cDNAs in a FANCM strain that carries
a FANCC-TAP tagged allele (FANCM FANCC-TAP).
Drug resistant clones were then tested for expression
and complementation of the various FANCM asso-
ciated defects, such as DNA damage induced FANCD2
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containing the exons encoding the helicase domain. The gene disruption strategy removes three exons coding for the conserved helicase domain.
Genomic Southern blot conﬁrms disruption of the helicase domain. Cartoon depicting predicted products generated by hypomorphic alleles in
FANCM deﬁcient cell lines (LMS—Large Middle Section). (B) Time course experiment of FANCD2 monoubiquitination in FANCM deﬁcient cell
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shown for 0-h and 6-h time point. FANCD2 monoubiquitination activation in FANCM-hel and FANCM cell lines is deﬁcient, but normal
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Nucleic Acids Research, 2009,Vol.37, No. 13 4363monoubiquitination (Figure 2B), cisplatin sensitivity
(Figure 2C), ability to interact with the FA core complex
(Figure 2D), chromatin targeting of the core complex
(Figure 2E) and ﬁnally SCEs (Figure 2F). The construct
containing the helicase domain (+HEL) partially rescues
the FANCD2 monoubiquitination defects (Figure 2B,
compare 18.9 monoubiquitination induction fold in
+HEL cell line to 12.2 shown by FANCM cell line)
and cisplatin sensitivity seen in FANCM cell line
(Figure 2C), it is able to form a stable FA core complex
and facilitates accumulation of this complex on chromatin
(Figure 2D and E). Moreover, the FANCM helicase
domain also partially suppresses elevated SCEs in the
FANCM null mutant (Figure 2F). The construct contain-
ing the nuclease domain of FANCM partially rescues
the FANCD2 monoubiquitination defect observed in
FANCM (Figure 2B, +NUC cell line shows 28.1 mono-
ubiquitination induction fold compared to 12.2 shown by
FANCM cell line) indicating that this function is redun-
dant to the helicase domain. It can also assemble into the
FA core complex (Figure 2D), however it does not rescue
cisplatin sensitivity or the elevated levels of SCE detected
in FANCM (Figure 2C and F). Finally, +LMS does
not complement any of the defects observed in FANCM
null cell line but importantly, it can interact with the FA
core complex (Figure 2D). These results indicate that the
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4364 Nucleic Acids Research, 2009, Vol. 37,No. 13helicase and nuclease domains play redundant roles in
FANCD2 ubiquitination process, however, only the heli-
case domain partially rescues FANCM cells from sensi-
tivity to cisplatin and to suppress elevated levels of SCEs
observed in the FANCM null cell line. As all the con-
structs can interact with the FA core complex, we also
conclude that LMS region is required to anchor
FANCM into this complex.
In the course of our studies of the FANCM strain we
noticed that this mutant was also sensitive to UV light and
camptothecin (CPT). This is not a feature shared with any
of the other FA gene knockouts (data not shown).
We decided to investigate this further by identifying the
section of FANCM that may be important for either UV
light or CPT tolerance. As can be seen in Figure 3A, the
FANCM strain is sensitive to UV light (D10 value –
WT=5.1J/m
2 FANCM=2.8J/m
2). However, this
sensitivity can be complemented with the construct con-
taining the helicase domain (D10 value-+HEL=4.7J/
m
2) (Figure 3B). A similar analysis was also carried
out for CPT sensitivity. Again we noted that FANCM
is sensitive to this agent (Figure 3C). CPT sensitivity,
in contrast to UV sensitivity, is partially complemented
by the construct containing the nuclease domain but
not by the helicase domain (Figure 3D). Cumulatively,
the results indicate that the region encompassing the heli-
case domain of FANCM promotes repair of UV light
damage, whilst that encompassing the nuclease domain
appears to be critical.
A point mutation in the helicase Walker B motif
separates SCE suppression from crosslink repair
functions of FANCM
We then focused our studies on the raised spontaneous
SCEs in the FANCM and FANCM-hel strains.
Genetic epistasis results indicate that these raised spon-
taneous SCEs are not simply due to a defective FA path-
way (Figure 1D). To determine whether the putative
helicase activity of FANCM suppresses SCEs, an inacti-
vating point mutation (DEAD to AEAD) was introduced
into the Walker B motif of this domain. The isolated
strain, FANCM-D203A (helicase domain disruption
in one allele and knockin into the second allele), con-
tains the relevant mutation in the genomic sequence
(Supplementary Figure 1) and importantly expresses full
length FANCM protein (Figure 4A). To our surprise,
we noted that the point mutant strain was proﬁcient
in monoubiquitinating FANCD2 (Figure 4A) and not
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Nucleic Acids Research, 2009,Vol.37, No. 13 4365sensitive to cisplatin (Figure 4B) indicating that the
Walker B motif is dispensable for crosslink repair. Next
we knocked in a TAP tag into the last exon of the FANCC
allele. This results in the expression of endogenously
TAP tagged FANCC which enables us to determine the
stability of the FA core complex in our point mutant cell
line (Figure 4C). In WT cells, the FA core complex
migrated in a peak corresponding to 1MDa. In
FANCM and FANCM-hel cell lines, this complex
eluted at a lower molecular weight when compared to
the wild type. However, the gel ﬁltration proﬁle for the
FANCM-D203A cell line was identical to the wild type
proﬁle, indicating that the FA core complex is intact
(Figure 4C). Strikingly, this mutant shows high levels of
SCEs (Figure 4D) demonstrating that the suppression of
SCEs can be attributed to the enzymatic activity of the
helicase domain of FANCM. Therefore, the Walker
B box mutation D203A dissociates the role of FANCM
in crosslink repair and FANCD2 monoubiquitination
from that in suppressing SCEs. Since FANCM and both
yeast FANCM orthologues also suppress crossover
recombination (9), this indicates that the SCEs suppres-
sion function of FANCM is conserved in evolution.
FANCM functions with the Bloom helicase to
suppress SCEs
The Blm helicase is the main guardian against SCEs
in eukaryotes (18). The yeast FANCM orthologues
function in a distinct SCE suppression pathway to their
respective Blm orthologues (9). In order to test whether
vertebrate FANCM functions in the same or a distinct
SCE suppression pathway to Blm, we made the helicase
point mutation D203A in a DT40 BLM knockout cell
line (Blm) (19) to obtain the cell line Blm FANCM-
D203A (Supplementary Figure 2). The double mutant
strain displayed the same viability as the single Blm
strain (Supplementary Figure 2). This strain was proﬁ-
cient at FANCD2 monoubiquitination although with
slightly reduced eﬃciency when compared to either single
mutant strain (Figure 5A). We also determined the
crosslink sensitivity and particularly noted that the Blm
FANCM-D203A strain retained the cisplatin sensitivity
of the Blm strain (Figure 5B). Most importantly, the
number of SCEs in the Blm FANCM-D203A strain
(mean=15.2 SCEs per metaphase) was equivalent to
the Blm strain (mean=14 SCEs per metaphase)
(Figure 5C).
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Figure 4. A Walker B point mutation in the helicase domain separates the role for FANCM in SCEs suppression from that in crosslink repair. (A)
FANCM immunoblot of nuclear extracts without ( ) or with (+) DNA damage. A full length FANCM protein is expressed in the knock in strain
that is phosphorylated following DNA damage. Below—the FANCD2 monoubiquitination process after DNA damage is not defective in FANCM-
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4366 Nucleic Acids Research, 2009, Vol. 37,No. 13Since FANCM functions within the FA core complex
and also with Blm to carry out distinct functions, we set
out to determine if the distribution of FANCM protein
complex(es) is/are altered in the absence of Blm or the FA
core complex. Nuclear extracts from wild-type, Blm and
FANCL DT40 strains were fractionated by size exclu-
sion chromatography and blotted for FANCM or the FA
core complex protein FANCG. The high molecular mass
FANCM complex is unperturbed in Blm cells but shifts
to a slightly smaller mass when the FA complex integrity
is disrupted, as seen in FANCL cells (Figure 5D). In
addition, FANCM is stable and it can be phosphorylated
in most chicken FA knockout cell lines (Figure 5E).
Together, these studies point to the existence of a distinct
stable FANCM complex that does not contain BLM or
the FA core complex. Cumulatively, these experiments
indicate that FANCM contributes only in a subset of
Blm suppressible SCE events.
DISCUSSION
In conclusion our systematic genetic dissection of chicken
FANCM reveals how this protein promotes activation of
the FA pathway and crosslink repair. In addition we dis-
covered that FANCM is not only required for tolerance of
UV and camptothecin induced DNA damage, but also for
the suppression of crossover recombination.
Monoubiquitination of FANCD2 is crucial for the acti-
vation of the FA pathway. This process requires an intact
FA core complex, Ube2t and FANCI, occurring only
during the S and G2 phases of the cell cycle (20). The
core enzymatic basis of this reaction is probably
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Nucleic Acids Research, 2009,Vol.37, No. 13 4367modulated by the E2 ligase (Ube2t) interacting with the
E3 (FANCL embedded in the core complex) and the sub-
strate (FANCD2 complexed to FANCI) (21–23). Studies
using siRNA knockdown of FANCM or its nuclease
domain binding partner FAAP24 in human cell lines
show that FANCD2 monoubiquitination is severely
impaired. In contrast, although chicken FANCM knock-
outs have reduced FANCD2 monoubiquitination, the
defect in this modiﬁcation is less marked than that
observed in human cell lines. Moreover, when the
FANCM strain is exposed to large doses of cisplatin
we can still see DNA damage induced FANCD2 mono-
ubiquitination. Despite this discrepancy, a question that
remains is how FANCM stimulates DNA damage induci-
ble FANCD2 monoubiquitination. This cannot simply be
due to assembly of the residual FA core complex existing
in the FANCM strain. One possibility is that FANCM
mobilizes the FA core complex to chromatin by recogniz-
ing damaged DNA replication forks (4,24). Indeed both
the helicase and nuclease domains can bind fork
structured DNA (4,7,8) and we show here that both
domains can independently stimulate FANCD2 monoubi-
quitination. However if stalled replication forks degener-
ate into double strand breaks in FANCM null cells, then
this may enable a residual FANCM deﬁcient core complex
to stimulate FANCD2 monoubiquitination.
A key function of the FA pathway is to promote DNA
crosslink repair. Genetic studies indicate that the FA pro-
teins work upstream of a combined HR and TLS process
to remove crosslinks (14). A recent report using Xenopus
extract provides biochemical proof of such a combined
process (25). We currently do not know the molecular
basis of the putative upstream role of the FA pathway
in such a combined process. However, FANCM clearly
plays a key role in this process and it may now be possible
using the genetic and biochemical evidence to integrate
this into a working model. Our study clearly shows that
the N-terminal helicase domain is crucial for eﬀective
repair, although a predicted inactivating mutation in
the helicase domain has no impact on crosslink repair.
Helicase LMS
ATP
D2 2
I
D2
I
Ub
Ub
Other repair
    factors
3
Stimulates FANCD2 monoubiquitination
Crosslink repair
SCE suppression
UV light tolerance
Anchors FANCM to FA core complex
Stimulates FANCD2 monoubiquitination
FAAP24 interaction
CPT tolerance
A
Ub
H
N
L
FANCM
FANCM
C B
2 1
H
N
L
FANCM
FA core 
complex
FA core 
complex
H
N
L
FANCM
FA core 
complex
Nuclease
Figure 6. Model for the role of FANCM in the DNA damage response. (A) Model for the role of FANCM in the FA pathway and crosslink repair
in the DNA damage response. (1) The helicase or nuclease domain can target the FA core complex to a replication block at a DNA crosslink. (2)
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4368 Nucleic Acids Research, 2009, Vol. 37,No. 13The biochemical activities of FANCM, such as branch
migration, translocase activity, D-loop dissolution and
fork regression, all require ATPase activity and are very
likely to be signiﬁcantly impacted by mutation of the
DEAD box. This suggests that these activities may not
confer crosslink repair activity to FANCM. On the
other hand, the siRNA complementation based approach
does suggest that ATP binding is required for crosslink
repair (13). It is therefore plausible that the ATP binding
in the context of an intact helicase domain is crucial for
crosslink repair, although this may not simply be used to
drive the helicase or translocase functions. We propose
that the helicase domain of FANCM recognizes and
binds to stalled replication forks. DNA dependent ATP
binding activity may then induce a conformational change
that recruits other repair proteins to the site (Figure 6A).
Such a model would predict that apart from FAAP24
other proteins might interact with FANCM.
An unexpected ﬁnding reported here is the marked sen-
sitivity to both UV light and camptothecin, interestingly
this is a feature it shares with hamster cell line mutant of
FANCG (26). FANCM seems to utilize diﬀerent domains
to protect against the genotoxic eﬀects of either of these
agents, revealing a new level of complexity in the repair
functions of this protein (Figure 6B). The helicase domain,
but not its translocase activity (data not shown), is
required to protect against UV light. However, it is not
possible from our genetic studies to deduce how the
FANCM helicase domain facilitates repair of UV light
induced DNA damage, creating double mutants where
FANCM disruption is combined with either NER or
TLS genes may shed important light into this question.
The marked sensitivity to camptothecin in the FANCM
knockout requires the region emcompassing the nuclease
domain. Camptothecin exerts its toxicity by covalently
trapping type I topoisomerases-DNA complexes. Such
complexes impede replication and are converted into
lethal double strand breaks. The nuclease domain appears
to have no obvious activity apart from binding to
FAAP24 and HCLK2, and to fork structured DNA.
Therefore, it could be that this FANCM domain can
target repair enzymes to replication forks stalled at
locked type I topoisomerases-DNA complexes. It is inter-
esting to note that Blm cells are also sensitive to CPT
and it has been suggested that the Blm-Topo III complex
helps resolve damage caused by this agent (27). Since
FANCM co-puriﬁes with the Blm-Topo III complex (28)
it is conceivable that the C terminus of FANCM recruits
the Blm-Topo III complex to resolve such stalled forks.
FANCM loss in DT40 results in an increase in sponta-
neous SCE events. These events could reﬂect the presence
of spontaneous DNA damage that is then resolved by
HR. In such a scenario it is possible that replication
fork breakage occurs more frequently in the absence of
FANCM resulting in the accumulation of double strand
breaks. Unrestrained homologous recombination may
then repair such lesions and since some of such events
are resolved by crossover this may result in raised SCE.
Alternatively and more likely the SCE events could be due
to a bias towards resolving recombination intermediates
by crossover. How might FANCM act to suppress
crossover recombination? Our studies clearly show that
this requires the Walker DEAD box motif, and this is a
distinct activity from the other FANCM based DNA
damage tolerance responses reported here. In addition,
our genetic studies show that FANCM functions in only
a subset of Blm dependent non-crossover events. It is also
noteworthy that both yeast FANCM orthologues—
MPH1 and FML1 also suppress crossover recombination.
However, in contrast to FANCM, both yeast FANCM
orthologues function in an independent pathway to their
respective Blm orthologues. Recombinant FANCM,
Mph1 and Fml1 can all dissolve D loops (Figure 6C)
(9,10,12). These recombination intermediates precede
crossover-resolving steps. By resolving such early recom-
bination intermediates, FANCM may indirectly reduce
crossover events. What might then be the function of
Blm in such situations? One possibility is that FANCM
synergises the function of Blm in dissolving D loops. The
fact that Blm seems to be more important than FANCM
in suppressing crossovers may reﬂect its key role in dec-
atenating double Holliday junctions (18). It will therefore
be important to test whether Blm augments the anti-
recombinogenic biochemical activities of FANCM.
Multiple DNA helicases in both budding yeast (Sgs1,
Srs2, Mph1) (29,30) and vertebrates (Blm, Wrn, Fbh1,
FANCM, RecQL1, RecQL5) (31–33) defend their gen-
omes from crossovers. The fact that mitotic eukaryotic
cells display very low levels of crossovers is a testament
to the evolutionary conserved function of these pathways.
Their inactivation leaves genomes vulnerable to loss of
heterozygosity, chromosome translocations and thereby
to inevitable consequences on health.
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